NV
ANTH

Nair Vinay’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Nair Vinay’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,429
Closed -$51K – 408
2015
Q1 		$51K Buy
+1,429
New +$42.3K 0.04% 376

Other funds holding ANTH

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Nair Vinay's ANTH Position: Q2 2015 in Review

Nair Vinay sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2015, closing a stake of 1,429 shares — an estimated $51K sold.

Nair Vinay first reported a position in ANTH in Q1 2015 and held it in 1 quarter. The position peaked at $51K in Q1 2015. 73 funds tracked by Wall St. Rank hold ANTH as of Q2 2015.

  • Nair Vinay reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Nair Vinay sold 1,429 Anthera Pharmaceuticals, Inc. shares in Q2 2015, an estimated $51K.
  • Nair Vinay first reported a position in Anthera Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Nair Vinay's Anthera Pharmaceuticals, Inc. position peaked at $51K in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2015.

Based on Nair Vinay's 13F filing for Q2 2015, filed 12 Aug 2015.